A Bivalent Omicron-Containing Booster Vaccine against Covid-19 | NEJM
Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR
FDA advisory panel recommends Omicron-containing booster shots
Bivalent mRNA booster effective, 'essential' for older adults
Effectiveness of Up-to-Date COVID-19 Vaccination in Preventing SARS-CoV-2 Infection Among Nursing Home Residents — United States, November 20, 2022–January 8, 2023 | MMWR
Evidence to recommendation Framework: Bivalent COVID-19 vaccine booster doses
Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study - The Lancet Infectious Diseases
Effectiveness of Covid-19 Vaccines over a 9-Month Period in North Carolina | NEJM
Potentially breaking the COVID-19 stalemate with variant booster, bivalent or polyvalent vaccines
Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study | The BMJ
Vaccines | Free Full-Text | Efficacy of the Second COVID-19 Vaccine Booster Dose in the Elderly
Vaccines | Free Full-Text | The Four Ws of the Fourth Dose COVID-19 Vaccines: Why, Who, When and What
Vaccine safety and efficacy : Oregon Health News Blog
Vaccines | Free Full-Text | Vaccine Confidence and Uptake of the Omicron Bivalent Booster in Tennessee: Implications for Vulnerable Populations
CDC publishes first estimates of bivalent boosters' effectiveness against XBB.1.5
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ...
Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study | The BMJ
Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study - The Lancet Infectious Diseases
Who Is Eligible for a COVID-19 Booster?
